New Zealand markets open in 5 hours 3 minutes

ILMN Dec 2024 240.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.70000.0000 (0.00%)
As of 09:30AM EDT. Market open.
Full screen
Previous close2.7000
Open2.7000
Bid1.1000
Ask1.6000
Strike240.00
Expiry date2024-12-20
Day's range2.7000 - 2.7000
Contract rangeN/A
Volume1
Open interest22
  • PR Newswire

    Illumina's planned divestment of GRAIL approved by the European Commission

    Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC).

  • Reuters

    UPDATE 2-EU approves Illumina's plan to divest cancer test maker Grail

    U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.

  • Reuters

    EU approves Illumina's plan to divest cancer test maker Grail

    BRUSSELS (Reuters) -U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.